Wells Fargo & Company Cogent Biosciences, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 30,144 shares of COGT stock, worth $313,497. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,144
Previous 26,853
12.26%
Holding current value
$313,497
Previous $180,000
41.11%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding COGT
# of Institutions
165Shares Held
114MCall Options Held
104KPut Options Held
163K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.5MShares$109 Million0.24% of portfolio
-
Commodore Capital LP New York, NY9.74MShares$101 Million7.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.26MShares$96.3 Million6.08% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$75.8 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$72.4 Million8.79% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $684M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...